Biocracked
←

#clinical-trial-results

1 article
Approach: the human outcome. Palette: bold color field.

A close, slightly high three-quarter view of a bare abdomen, cropped at the ribs and hips with no face. A hand in an electric green (#00e676) nitrile glove pinches a fold of belly skin and holds a slim syringe with the needle just about to enter. Faint yellow-purple bruising near the injection site hints at the side effects. The torso fills the frame against a flat, saturated teal backdrop that contrasts with the warm skin tones. Soft, even studio light from the left gives gentle shadows and visible skin texture, with fine pores and small hairs. The syringe tip is in sharp focus and the background falls away. No text or markings anywhere. The mood is clinical, unsentimental and skeptical.
research

Does CBL-514 really burn fat? Here's what we know

BY HELIX WARD ·

The 2025 Phase 2 CBL-514 trial did not test weight loss. It tested whether an abdominal injection could cut at least 150 mL of subcutaneous fat volume on ultrasound, and 69.6% (16/23) of treated participants got there at 8 weeks versus 0/16 on placebo. But mean body weight did not fall (+0.02 kg), nearly half of treated participants did not complete the study, and the per-protocol group was just 30 people. Injection-site reactions were common, including discoloration in 71.4% and severe pain in 18.4%. Here is the data-first breakdown of what the trial shows and what it doesn't.

This page is available in